By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > ARB > Olmesartan

Olmesartan

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
6 Min Read
SHARE
4 min read|713 words

Olmesartan Drug Profile

What is Olmesartan?

Olmesartan is an angiotensin receptor blocker (ARB) medication primarily used to treat high blood pressure (hypertension). It belongs to a class of drugs that work by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. By preventing this constriction, olmesartan helps lower blood pressure and reduces the workload on the heart.

Uses

  • Hypertension (High Blood Pressure): The primary FDA-approved use for olmesartan is treating high blood pressure in adults and children 6 years and older. It can be used alone or in combination with other antihypertensive medications.
  • Cardiovascular Risk Reduction: By effectively controlling blood pressure, olmesartan may help reduce the risk of heart attacks, strokes, and other cardiovascular complications associated with hypertension.
  • Combination Therapy: Often prescribed alongside diuretics or calcium channel blockers when single-drug therapy is insufficient to achieve target blood pressure goals.
  • Diabetic Nephropathy Protection: While not specifically approved for this use, ARBs like olmesartan may provide kidney-protective benefits in diabetic patients with hypertension.
  • Heart Failure Management: Sometimes used as an alternative to ACE inhibitors in patients with heart failure who cannot tolerate ACE inhibitors due to side effects like persistent cough.

How it works

Olmesartan blocks angiotensin II receptors in blood vessel walls, preventing this powerful hormone from binding to its target sites. Angiotensin II normally causes blood vessels to narrow and promotes sodium retention, both of which increase blood pressure. By blocking these effects, olmesartan allows blood vessels to remain relaxed and dilated, resulting in lower blood pressure and improved blood flow throughout the body.

Side effects

Common side effects:

  • Dizziness or lightheadedness
  • Headache
  • Fatigue or weakness
  • Upper respiratory tract infections
  • Back pain
  • Nausea
  • Diarrhea
  • Low blood pressure (hypotension)

Serious side effects to watch for:

Submit Your Paper
GMJ_Submit_Banner
  • Severe diarrhea with substantial weight loss (sprue-like enteropathy)
  • High potassium levels (hyperkalemia) causing irregular heartbeat
  • Kidney problems or worsening kidney function
  • Severe allergic reactions including swelling of face, lips, or throat
  • Extremely low blood pressure causing fainting

Warnings and precautions

  • Pregnancy: Olmesartan can cause serious harm or death to developing babies and should not be used during pregnancy, especially in the second and third trimesters. Women should use effective contraception while taking this medication.
  • Kidney disease: Patients with severe kidney impairment or those on dialysis may need dose adjustments or alternative treatments. Regular monitoring of kidney function is recommended during treatment.
  • Liver impairment: Those with severe liver disease may require lower starting doses as the medication is processed by the liver.
  • Dehydration risk: Patients who are volume-depleted due to diuretic therapy, dietary salt restriction, or illness may experience excessive blood pressure lowering when starting olmesartan.
  • Elderly patients: Older adults may be more sensitive to blood pressure-lowering effects and may require careful dose titration and monitoring.

Interactions

  • ACE inhibitors: Combining with medications like lisinopril or enalapril increases the risk of kidney problems and high potassium levels.
  • Potassium supplements and salt substitutes: Can lead to dangerously high potassium levels when combined with olmesartan.
  • Diuretics: Water pills can enhance blood pressure-lowering effects, potentially causing excessive hypotension, especially when starting treatment.
  • NSAIDs: Anti-inflammatory drugs like ibuprofen or naproxen may reduce olmesartan’s effectiveness and increase kidney damage risk.
  • Lithium: Olmesartan may increase lithium levels in the blood, potentially leading to lithium toxicity.
  • Diabetes medications: May enhance blood sugar-lowering effects, requiring glucose monitoring and possible dose adjustments.
  • Colesevelam: This cholesterol medication can reduce olmesartan absorption if taken simultaneously; doses should be separated by at least 4 hours.
  • Alcohol: Can amplify blood pressure-lowering effects and increase dizziness risk.

Check interactions with the GMJ Interaction Checker

Dosage

For adults with hypertension, the typical starting dose is 20 mg taken once daily, with or without food. The dose may be increased to 40 mg daily after 2 weeks if blood pressure is not adequately controlled. The maximum recommended dose is 40 mg per day. For pediatric patients 6-16 years old weighing 20-35 kg, the usual starting dose is 10 mg once daily, while those weighing more than 35 kg typically start with 20 mg daily. All dosage decisions should be individualized by a healthcare provider based on blood pressure response, kidney function, and other patient factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Olmesartan." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/olmesartan/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Vitamin D dose response is not linear: Why shelf-picked supplements may not work as expected

Vitamin D supplements do not work the same way for everyone. Research…

How a single stem cell in bone marrow generates your entire immune system

All blood and immune cells originate from a single pluripotent hematopoietic stem…

How amino acids shape brain function: neurotransmitters, energy, and cognitive resilience

Amino acids are the precursors to neurotransmitters and metabolic substrates for brain…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Telmisartan

By
Prof. Giorgi Pkhakadze
02/06/2026

Azilsartan

By
Prof. Giorgi Pkhakadze
02/06/2026

Irbesartan

By
Prof. Giorgi Pkhakadze
02/06/2026

Telmisartan

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up